logo
FDA adds new blue food dye from gardenia fruit

FDA adds new blue food dye from gardenia fruit

UPI2 days ago
U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. testifies at a House committee on June 24. The FDA on Monday approved the use of a new blue color additive from the gardenia fruit, the fourth coloring from natural sources added in the last two months. Photo by Annabelle Gordon/UPI. | License Photo
July 14 (UPI) -- The U.S. Food and Drug Administration on Monday approved the use of a new blue color additive from the gardenia fruit, the fourth coloring from natural sources added in the last two months.
The blue color, which comes from the white flowering evergreen, can be used for sports drinks, flavored or enhanced non-carbonated water, fruit drinks, ready-to-drink teas plus hard and soft candy, the FDA said in a news release.
The health agency also announced a letter was sent to manufacturers encouraging them to phase out Red No. 3 in foods sooner than Jan. 15, 2027, which is the required deadline announced in April by Health and Human Services Secretary Robert F. Kennedy Jr. The dye has been linked to cancer in rats at high amounts.
At that time, Kennedy announced measures to work with the industry to phase out petroleum-based synthetic dyes in food. They have committed to ending 40% of the additives.
"Every day, children are exposed to synthetic chemicals in food that serve no purpose," Kennedy said in a news release. "The FDA's approval of gardenia blue shows we're finally putting kids first. Thanks to Dr. Marty Makary's bold leadership, we're cutting through industry influence and taking decisive action to make American Healthy Again."
Makary, the FDA commissioner, said: "Now, by extracting the palette of available colors derived from natural sources, food manufacturers have a variety of options available that will make it easier to end their use of petroleum-based dyes."
The coloring is made by refining the compound genipin. It is derived from crushed gardenia jasminoides Ellis fruit, which often is used in traditional Chinese medicine.
Soy, which is a potential allergen, is used to make gardenia blue, but the group said it is detected in the additive and won't cause allergic reactions.
Gardenia Blue Interest Group asked to exempt it from labeling. The FDA on July 9 said it is reviewing the request.
In May, three other colors were approved: galdieria extract blue, white calcium phosphate and butterfly pea flower extract in blue, purple and green.
Color additives must be approved by the FDA before they may be used in foods.
On Friday, Consumer Brands announced a voluntary commitment to encourage makers of consumer packaged goods and beverage products to remove certified Food, Drug and Cosmetic colors from products served in schools nationwide by the start of the 2026-2027 school year.
The International Association of Color Manufacturers said in a news release that artificial dyes are "essential for consistency, visual appeal and consumer trust in food products."
Several major food companies are removing synthetic food colorings from their products, including Kraft Heinz and General Mills by the end of 2027.
But Mars, which makes M&M's and Skittles, said it will continue using the synthetic dyes in its candies, reversing a pledge the company made in 2016 to remove artificial colors from all foods and snacks.
The company told The New York Times that its products are "safe to enjoy and meet the high standards and applicable regulations set by food safety authorities around the world."
A spokesman for the National Confectionery Association, Christopher Gindlesperger, told the New York Post: "People can freely use cannabis, THC products, alcohol and cigarettes but vibrantly colored candy is an issue? Ge me a break."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump says Coke agrees to use cane sugar in US
Trump says Coke agrees to use cane sugar in US

Yahoo

timean hour ago

  • Yahoo

Trump says Coke agrees to use cane sugar in US

President Donald Trump said Wednesday beverage giant Coca-Cola has agreed to use cane sugar in its iconic drink in the U.S. "I have been speaking to Coca-Cola about using REAL Cane Sugar in Coke in the United States, and they have agreed to do so," Trump said in a post on his Truth Social platform. "I'd like to thank all of those in authority at Coca-Cola. This will be a very good move by them — You'll see. It's just better!" In a brief statement on its website, Coca-Cola said: "We appreciate President Trump's enthusiasm for our iconic Coca‑Cola brand. More details on new innovative offerings within our Coca‑Cola product range will be shared soon." High-fructose corn syrup has been Coca-Cola's primary sweetener in U.S. products since 1985. The company currently uses cane sugar in products sold in several other markets, including Mexico, the United Kingdom, Africa and the Middle East. The company also sells a limited amount of Coke in the U.S. made with sugar as a kosher option for Passover -- distinguished by its yellow caps, instead of red. A noted Diet Coke enthusiast, Trump's relationship with the beverage giant has been well-documented. Ahead of the inauguration for his second term, Trump received a special Presidential Commemorative Inaugural Diet Coke bottle from Coca-Cola Company Chairman and CEO James Quincey. Why the change? Trump didn't specify a reason for the change. However, the announcement comes as Robert F. Kennedy Jr.'s "Make America Healthy Again" initiative gains traction, which advocates for removing HFCS from American food products. The initiative cites research linking HFCS to various health issues that contributes to obesity and chronic illness. However, studies are mixed on whether cane sugar is healthier than HFCS, with research suggesting that any added sugars, regardless of what type, increase the risk of Type 2 diabetes and other diseases. Dietitians recommend limiting added sugars of all varieties to less than 50 grams per day for most adults. One 12-ounce can of Coke has roughly 39 grams of sugar. Coke's switch from sugar to corn syrup Coca-Cola's 1985 transition to high-fructose corn syrup in the United States was primarily a business decision, the company said. The change coincided with rising sugar prices and agricultural policies that made corn syrup a more economical alternative. Solve the daily Crossword

Trump signs HALT Fentanyl Act to reclassify opioid as Schedule 1 drug
Trump signs HALT Fentanyl Act to reclassify opioid as Schedule 1 drug

UPI

time3 hours ago

  • UPI

Trump signs HALT Fentanyl Act to reclassify opioid as Schedule 1 drug

1 of 9 | President Donald Trump watches as Greg Swan, who lost his son Drew to fentanyl, speaks before signing the HALT Fentanyl Act during a ceremony in the East Room of the White House on Wednesday. The bill permanently places fentanyl-related substances into Schedule 1 of the Controlled Substances Act. Photo by Bonnie Cash/UPI | License Photo July 16 (UPI) -- President Donald Trump on Wednesday signed bipartisan legislation that attempts to curb the illegal flow of fentanyl into the United States by reclassifying the opioid as a Schedule 1 drug under the Controlled Substances Act. Trump appeared in the White House's East Room with supporters, including members of Congress and three people who described the deaths of family members from the opioid. The Halt All Lethal Trafficking of Fentanyl Act, or HALT Fentanyl Act, enacts harsher penalties for those convicted of offenses related to the drug. Under the law, fentanyl-related substances are triggered by the same quantity thresholds as analogues -- 100 grams or more and a 10-year mandatory minimum prison sentence. During Trump's first term in office, fentanyl analogues were temporarily listed as under Schedule 1. Analogues are substances chemically similar to the regular drug. "This is a very special time because we've worked very hard to put ourselves in this position," Trump said. "Today we strike a righteous blow to the drug dealers, narcotic traffickers and criminal cartels that we've all been hearing so much about for so many years and little has been done. "And we take a historic step toward justice for every family member touched by the fentanyl scourge." Ann Funder, who spoke to the Republican National Convention last July, lost her 15-year-old son Watson in 2022 to fentanyl poisoning. Gregory Swan's son Drew died in 2013, also from fentanyl poisoning, and he formed Fentanyl Fathers, who tell their tragic stories to high schools nationwide. Jacqueline Siegel founded Victoria Voice after the 2015 death of her 18-year-old daughter, Victoria, to a fentanyl overdose; and her sister died from cocaine laced with fentanyl this year. The bill overwhelmingly passed in both chambers: 321-104 in the House and 84-16 in the Senate. President Joe Biden supported the legislation, but it stalled in the Democratic-controlled Senate. "Despite tens of thousands of Americans dying from fentanyl overdose each year, Democrats refused to pass this commonsense bill when they controlled Congress and the White House," Sen. Chuck Grassley, of Iowa, the chairman of the Judiciary Committee, said after the passage on June 12. "I'm proud to see Republicans take real action to combat the fentanyl crisis, advance life-saving research and support our brave men and women in blue." "I want to thank President Trump for his continued commitment to keeping illicit substances out of our country, and the HALT Fentanyl Act works directly in line with that mission," U.S. Rep. Brett Guthrie of Kentucky said Wednesday. "As the Chairman of the House Committee on Energy and Commerce, I'm proud to have been a part of creating such critical legislation that permanently places fentanyl-related substances into Schedule I of the Controlled Substance Act to ensure law enforcement can crack down on drug traffickers that have wrought havoc on our communities for too long." The bill established an alternative registration process for certain Schedule 1 research. Nine major medical associations, more than 40 major advocacy groups and law enforcement groups representing 1 million officers supported the bill. In 2024, there were 48,422 deaths involving synthetic opioids, primarily fentanyl in the United States with 76,282 in 2023, according to the Centers for Disease Control and Prevention. In 2013, it was just 3,017 overdoses. Trump has tied some tariffs on imported goods to the flow of fentanyl from other countries, including China, Canada and Mexico. "Six months ago, we came into office and inherited the worst drug crisis in American history by far," Trump said. "They did nothing. For four long years, Joe Biden surrendered our borders to the most evil and vicious traffickers, and networks and everything else on the planet Earth, allowing foreign drug cartels to carve out a massive footprint on American soil. ... This open borders nightmare flooded our country with fentanyl and with people that shouldn't be here." He has designated the Mexican drug cartels as foreign terrorist organizations. And on his first day in office on Jan. 20, ordered the creation of Homeland Security task forces on illegal drugs. Through June, there have been 9,200 pounds of fentanyl seized with 21,900 for the entire 2024 at the border. Last month, were a record-low 8,024 U.S. Border Patrol apprehensions. In December 2023, there were 251,178 apprehensions. This week in Washington President Donald Trump holds a bilateral meeting with the Crown Prince and Prime Minister of Bahrain, Salman bin Hamad Al Khalifa, in the Oval Office of the White House on Wednesday. Photo by Aaron Schwartz/UPI | License Photo

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

Boston Globe

time4 hours ago

  • Boston Globe

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

Advertisement While painful, investors viewed the restructuring as a positive move ensuring the company would survive the recent string of bad news. Sarepta's stock price rose more than 50 percent to $28 per share in Wednesday's after-hours trading session. The stock closed the day at $18 per share, down 85 percent this year and a nine-year low. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up At its peak, the gene therapy, Elevidys, was projected to bring in over $3 billion per year. Now, the company has pulled it off the market for any Duchenne patients who use wheelchairs — most children and young adults with the condition over the age of 12. Elevidys remains available for younger Duchenne patients who can still walk, but Sarepta management has conceded that safety concerns are causing physicians and families to proceed with more caution, forcing the company to withdraw its sales forecast. Advertisement CEO Doug Ingram said in May the company would work to make the therapy available again for all patients, with improved protocols to mitigate safety concerns. But it likely faces an uphill battle, particularly given the Food and Drug Administration's new leadership. Vinay Prasad, director of the division that regulates gene therapies said in March, before his appointment, that Elevidys 'doesn't work but kills kids.' On Wednesday, the company said it will discuss with the FDA its plan to test the new protocol in a new cohort of an ongoing clinical trial, before trying to make Elevidys available again for older patients. At the FDA's request, Sarepta has agreed to add a so-called 'black box' safety warning to the Elevidys prescribing label, warning physicians about the risk of acute liver injury and liver failure associated with the gene therapy. Competition also looms. Two other gene therapies from rival companies are nearing approval. So are newer, more targeted versions of the company's so-called exon-skipping drugs, which have earned Sarepta over $4 billion despite little data showing they slow the progression of Duchenne. The company discontinued its own efforts at next-generation skippers over safety concerns. In its announcement, Sarepta said it will invest further in bringing forward a series of RNA medicines it recently licensed as it tries to chart a new future.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store